BLOG

endpoints

After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy

“Their Phase I data was stellar, great Phase I, and then they had this Phase II that failed primarily because they added the wrong drug,” Asher Nathan, CEO and co-founder of NeoTX, told Endpoints News as he unveils $45 million in new financing.